Compelling clinical evidence demonstrated that sufficient amounts of tumor-infiltrating lymphocytes (TILs) were essential for PD-1/PD-L1 blockade response and improved prognoses in many solid tumors [50]. The gene discussed is PDCD1; the disease is neoplasm.